Lung Cancer Screening Market Insights, Growth Forecast to 2029

mangesh

Jan 5, 2023 • 4 min read

lung Cancer Screening Market size was valued at USD 2.18 Billion in 2021 and the total Lung Cancer Screening revenue is expected to grow at a CAGR of 8.32% from 2022 to 2029, reaching nearly USD 4.13 Billion.

lung Cancer Screening Market Overview:

The lung Cancer Screening market research report looks into and analyses the market's position during the predicted period. It is an in-depth study that focuses on fundamental and secondary drivers, market dominance, key segments, and geographic analysis. The research also looks at notable individuals, large collaborations, mergers, and acquisitions, as well as contemporary innovation and corporate strategy.

Market Scope:

We examined the lung Cancer Screening Market from every angle conceivable, including both primary and secondary research methodologies. This helped us better grasp current market dynamics such as supply-demand imbalances, pricing trends, product preferences, and consumer behaviour. The information is then gathered and evaluated using a variety of market estimations and data validation procedures. In addition, we have an in-house data forecasting engine that predicts market growth until 2027.

Get a Sample PDF of the Report at :@ https://www.maximizemarketresearch.com/request-sample/166924

Segmentation:

Based on Cancer Type, the Non-small Cell Lung Cancer (NSCLC) segment dominated the global lung cancer screening market with the highest market share of 78% in 2021. This segment is further expected to maintain its dominance with the highest market share of 85% at the end of the forecast period. Non-small cell lung cancer (NSCLC) is the most common type of cancer, accounting for 85% of lung cancer occurrences. However, NSCLC subtypes include large cell carcinoma, adenocarcinoma, squamous cell carcinoma, and other less common types of NSCLC. Increased screening awareness in developed and developing countries, along with an increase in NSCLC incidence globally, is expected to drive segment growth over the forecast period. As a result, during the forecast period, the segment is expected to grow at an 8.24% CAGR. According to the American Cancer Society, approximately 84% of all lung malignancies are non-small cell, while 13% are SCLC. Meanwhile, according to Cancer.Net, the five-year survival rate for NSCLC is 24%, compared to 6% for SCLC.

Key Players:

• GE Healthcare (United States)
• PenRad Technologies, Inc. (United States)
• NanoString, Myriad Genetics Inc. (United States)
• OncoCyte (United States)
• Biodesix (United States)
• Broncus (United States)
• Abbott (United States)
• Illumina, Inc., (United States)
• Thermo Fischer Scientific (United States)
• Medtronic (United States)
• Nuance Communications, Inc. (United States)
• Riverain Tech (United States)
• 20/20 Gene Systems (United States)
• Danaher Corporation (United States)

Primary and secondary research are used to identify market leaders, as well as primary and secondary research to assess market revenue. As part of the core study, in-depth interviews with major thought leaders and industry specialists such as experienced front-line personnel, CEOs, and marketing professionals were done. In-depth interviews with notable thought leaders and industry specialists, such as experienced front-line personnel, CEOs, and marketing professionals, were conducted as part of primary research, while secondary research included a review of the major manufacturers' annual and financial reports. Secondary data is utilised to compute percentage splits, market shares, growth rates, and global market breakdowns that are then compared to historical data. The following players are featured in this report:

Regional Analysis:

The research examines the local industry in-depth, utilizing both qualitative and quantitative data. It provides an overview and prediction of the global lung Cancer Screening market segment by segment. It also provides market size and forecast projections for five key regions from 2021 to 2027, including North America, Europe, Asia-Pacific, the Middle East & Africa, and South America. The lung Cancer Screening market in each area is further segmented into regions and sectors. The research studies and anticipates a wide range of nations, as well as current trends and opportunities in the sector.

COVID-19 Impact Analysis on lung Cancer Screening Market:

We thoroughly researched and analyzed the Global lung Cancer Screening Market Development Strategy post-COVID-19, by corporate strategy analysis, landscape, type, application, and leading countries, which encompasses and analyses the global lung Cancer Screening industry's potential, providing statistical data on market dynamics, growth factors, major challenges, PORTER analysis, and market entry strategy analysis, opportunities, and forecasts. The study's main goal is to provide industrial enterprises with a strategic analysis of COVID-19's impact. This analysis looked at the marketplaces of key countries at the same time and emphasized their market potential.

Key Questions Answered in the lung Cancer Screening Market Report are:

What are the most promising high-growth opportunities in the global lung Cancer Screening sector, as defined by product category, End User, and Region?
Which lung Cancer Screening market segments will expand the fastest, and why?
Which areas will expand the fastest, and why?
What are the primary elements influencing lung Cancer Screening market dynamics? What are the primary drivers and obstacles in the lung Cancer Screening market?
What are the lung Cancer Screening market's business risks and dangers?

About Us:

MAXIMIZE MARKET RESEARCH PVT. LTD.

3rd Floor, Navale IT Park Phase 2,

Pune Banglore Highway,

Narhe, Pune, Maharashtra 411041, India.

Email: sales@maximizemarketresearch.com

Phone No.: +91 20 6630 3320

Website: www.maximizemarketresearch.com

Sign up for more like this.